99 related articles for article (PubMed ID: 37625197)
21. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
22. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Park K; Vansteenkiste J; Lee KH; Pentheroudakis G; Zhou C; Prabhash K; Seto T; Voon PJ; Tan DSW; Yang JCH; Wang J; Babu KG; Nakayama Y; Alip A; Chua KLM; Cheng JC; Senan S; Ahn YC; Kim TY; Ahn HK; Peters S; Yoshino T; Douillard JY
Ann Oncol; 2020 Feb; 31(2):191-201. PubMed ID: 31959336
[TBL] [Abstract][Full Text] [Related]
23. Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'.
Grössmann N; Wolf S; Rothschedl E; Wild C
ESMO Open; 2021 Jun; 6(3):100166. PubMed ID: 34087744
[TBL] [Abstract][Full Text] [Related]
24. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
25. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Haanen J; Obeid M; Spain L; Carbonnel F; Wang Y; Robert C; Lyon AR; Wick W; Kostine M; Peters S; Jordan K; Larkin J;
Ann Oncol; 2022 Dec; 33(12):1217-1238. PubMed ID: 36270461
[No Abstract] [Full Text] [Related]
26. Differential research impact in cancer practice guidelines' evidence base: lessons from ESMO, NICE and SIGN.
Pallari E; Fox AW; Lewison G
ESMO Open; 2018; 3(1):e000258. PubMed ID: 29344408
[TBL] [Abstract][Full Text] [Related]
27. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
Kiesewetter B; Raderer M; Prager GW; Fuereder T; Marosi C; Preusser M; Krainer M; Locker GJ; Brodowicz T; Zielinski CC
ESMO Open; 2017; 2(3):e000166. PubMed ID: 28761758
[TBL] [Abstract][Full Text] [Related]
28. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.
Califano R; Karamouzis MV; Banerjee S; de Azambuja E; Guarneri V; Hutka M; Jordan K; Kamposioras K; Martinelli E; Corral J; Postel-Vinay S; Preusser M; Porcu L; Torri V
Lung Cancer; 2014 Jul; 85(1):74-80. PubMed ID: 24746176
[TBL] [Abstract][Full Text] [Related]
29. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion.
Bendifallah S; Canlorbe G; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Huguet F; Cortez A; Daraï E; Ballester M
Br J Cancer; 2014 May; 110(11):2640-6. PubMed ID: 24809776
[TBL] [Abstract][Full Text] [Related]
30. Desmoid tumors: To treat or not to treat, That is the question.
Kasper B; Raut CP; Gronchi A
Cancer; 2020 Dec; 126(24):5213-5221. PubMed ID: 33022074
[TBL] [Abstract][Full Text] [Related]
31. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
González-Martín A; Harter P; Leary A; Lorusso D; Miller RE; Pothuri B; Ray-Coquard I; Tan DSP; Bellet E; Oaknin A; Ledermann JA;
Ann Oncol; 2023 Oct; 34(10):833-848. PubMed ID: 37597580
[No Abstract] [Full Text] [Related]
32. Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
Del Paggio JC; Azariah B; Sullivan R; Hopman WM; James FV; Roshni S; Tannock IF; Booth CM
Ann Oncol; 2017 Jan; 28(1):157-162. PubMed ID: 27742650
[TBL] [Abstract][Full Text] [Related]
33. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
34. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.
Colombo N; Creutzberg C; Amant F; Bosse T; González-Martín A; Ledermann J; Marth C; Nout R; Querleu D; Mirza MR; Sessa C;
Ann Oncol; 2016 Jan; 27(1):16-41. PubMed ID: 26634381
[TBL] [Abstract][Full Text] [Related]
35. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
Yoshino T; Arnold D; Taniguchi H; Pentheroudakis G; Yamazaki K; Xu RH; Kim TW; Ismail F; Tan IB; Yeh KH; Grothey A; Zhang S; Ahn JB; Mastura MY; Chong D; Chen LT; Kopetz S; Eguchi-Nakajima T; Ebi H; Ohtsu A; Cervantes A; Muro K; Tabernero J; Minami H; Ciardiello F; Douillard JY
Ann Oncol; 2018 Jan; 29(1):44-70. PubMed ID: 29155929
[TBL] [Abstract][Full Text] [Related]
36. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.
Colombo N; Creutzberg C; Amant F; Bosse T; González-Martín A; Ledermann J; Marth C; Nout R; Querleu D; Mirza MR; Sessa C;
Radiother Oncol; 2015 Dec; 117(3):559-81. PubMed ID: 26683800
[TBL] [Abstract][Full Text] [Related]
37. Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29].
Zucca E; Arcaini L; Buske C; Johnson PW; Ponzoni M; Raderer M; Ricardi U; Salar A; Stamatopoulos K; Thieblemont C; Wotherspoon A; Ladetto M;
Ann Oncol; 2023 Mar; 34(3):325. PubMed ID: 36529567
[No Abstract] [Full Text] [Related]
38. Corrigendum to "Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 32 (2021) 439-451].
Baudin E; Caplin M; Garcia-Carbonero R; Fazio N; Ferolla P; Filosso PL; Frilling A; de Herder WW; Hörsch D; Knigge U; Korse CM; Lim E; Lombard-Bohas C; Pavel M; Scoazec JY; Sundin A; Berruti A;
Ann Oncol; 2021 Nov; 32(11):1453-1455. PubMed ID: 34598840
[No Abstract] [Full Text] [Related]
39. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.
Zagouri F; Liakou P; Bartsch R; Peccatori FA; Tsigginou A; Dimitrakakis C; Zografos GC; Dimopoulos MA; Azim HA
Breast; 2015 Aug; 24(4):513-23. PubMed ID: 25818651
[TBL] [Abstract][Full Text] [Related]
40. The European Society for Medical Oncology (ESMO) and its activities through the Central Eastern European Task Force.
Hansen HH; Bjerre-Jepsen M; Hossfeld D
Ann Oncol; 1999; 10 Suppl 6():9-13. PubMed ID: 10676547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
